Indication
Esophagogastric Junction Adenocarcinoma
10 clinical trials
8 products
8 drugs
Clinical trial
A Multi-Center, Multi-Cohort Study of the Efficacy and Safety of Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-regimen-failed Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-08-25
Drug
AnlotinibDrug
TQB2450Product
Albumin-Bound PaclitaxelClinical trial
Neoadjuvant Sintilimab Plus SOX in the Locally Advanced Esophagogastric Junction Adenocarcinoma: a Prospective, Single Arm Phase II TrialStatus: Recruiting, Estimated PCD: 2024-01-01
Product
SintilimabClinical trial
Perioperative S-1 Plus Oxaliplatin Combined With Serplulimab or Placebo for Locally Advanced Gastric Adenocarcinoma With Proficient Mismatch Repair: a Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled StudyStatus: Recruiting, Estimated PCD: 2026-04-30
Drug
S1Drug
mFOLFOX6Product
SerplulimabDrug
VarlilumabClinical trial
Perioperative S-1 Plus Oxaliplatin Combined With Toripalimab or Toripalimab Monotherapy Versus S-1 Plus Oxaliplatin for Treatment of dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Randomized Controlled StudyStatus: Recruiting, Estimated PCD: 2026-02-28
Drug
PD-1 antibodyDrug
FOLFOXIRIClinical trial
Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2026-07-28
Clinical trial
A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Drug
TrastuzumabProduct
FLOTClinical trial
Tucidinostat in Combination With PD-1 Inhibitor and Bevacizumab as Late-line Treatment in Patients With Advanced Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction and Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-12-01
Product
TucidinostatClinical trial
The Efficacy and Safety of Anti-PD-1 Combined With Thymosin and SOX in Neoadjuvant Treatment of cStage IIII Gastric or Esophagogastric Junctional Adenocarcinoma: A Prospective, Open-label, Single-arm, Phase II Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility StudyStatus: Recruiting, Estimated PCD: 2025-05-31
Product
AdebrelimabClinical trial
A Single Arm, Multicenter Phase II Clinical Study of TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Oxaliplatin, Capecitabine in the First-line Treatment of Advanced Gastric Cancer (GC) or Adenocarcinoma of Esophagogastric Junction (AEG)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TQB2450